-
eLife: New insights into macular degeneration in old age
Time of Update: 2020-12-27
"Our study in the mouse model defined the cell types that cause inflammatory body-mediated inflammation in AMD and revealed specific roles and contributions of the NLRP3 protein and non-NLRP3-related inflammatory signals," he said.
-
PLoS Med: High BMI does not inhibit bacterial infections
Time of Update: 2020-12-27
, senior author of the paper and an associate professor in the Department of Chronic Disease Epidemiology, said the genetic analysis could help dispel the bias about the relationship between previous BMI and blood infections.
-
Losing weight in addition to keeping your mouth open, you also need to mobilize your mitochondrials
Time of Update: 2020-12-27
All in all, this study reveals a new pattern of immune metabolism disorders in which cells, such as fat cells, transfer their mitochondrials to macrophages to regulate the metabolic stability of the system.
-
Platinum Pharmaceuticals and the University of Ulysses announced a licensing agreement with AbbVie for the new coronary antibody and launched clinical trials
Time of Update: 2020-12-27
HK) and the University of Utrecht announced that ABBV-47D11, an all-human source and antibody authorized by AbbVie for COVID-19 and related coronavirus prevention and treatment, has conducted a phase I clinical trial.
-
Nature: Scientists have successfully developed a functional proteomic blueprint for E. coli that promises to reveal the function and interoperability of different genes in cells
Time of Update: 2020-12-27
coli mutants, each with a footprint removed, and then used TPP technology to conduct a deep analysis of the mutants and observe how all proteins in cells are expressed and how they denature, and the results may help researchers analyze the function and interaction of each protein, including hundreds of proteins that scientists do not currently know about.
-
The results of two clinical trials in NEJM show that new gene therapy may be available to treat sickle cell anemia
Time of Update: 2020-12-27
the first study, researchers used crispr-Cas9 gene editing systems to enhance fetal hemoglobin production in the body of patients with sickle cell anemia.
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia, New England Journal of Medicine (2020).
-
New anti-inflammatory drugs! AbbVie oral JAK1 inhibitor Rinvoq is recommended by CHMP in the European Union for the treatment of 2 new rheumatoids!
Time of Update: 2020-12-27
December 15, 2020 // -- AbbVie recently announced that the European Medicines Agency (EMA) Human Pharmaceutical Products Committee (CHMP) has issued an active review recommending approval of Rinvoq (upadacitinib) for two new rheumatoid adaptations: the treatment of active psoriasis arthritis (PsA) in adult patients and active spina bifida (AS) adult patients.
-
JEM: Targeting special T-cell proteins may inhibit the development of type 1 diabetes
Time of Update: 2020-12-27
DECEMBER 14, 2020 // -- In a recent study published in the international journal Journal of Laboratory Medicine, scientists from the University of Utah School of Medicine and others identified a new therapeutic target or could help treat type 1 diabetes patients by inhibiting a protein called OCA-B or protecting mice from the activity of β cells that destroy insulin-producing cells in the pancreas.
-
The first new bone marrow fibrosis drug in nearly a decade! Hundred-time Meishi Shiguibao JAK2 inhibitor Inrebic EU is about to be approved, has been listed in the United States!
Time of Update: 2020-12-27
December 15, 2020 / -- BMS recently announced that the European Medicines Agency (EMA) Committee on Human Pharmaceutical Products (CHMP) has issued a positive review recommending approval of the high
-
Colorectal Cancer (CRC) Precision Medicine! Mercadon Keytruda is recommended by THECHMP for approval: first-line treatment MSI-H/dMMR metastasis CRC!
Time of Update: 2020-12-27
December 14, 2020 // -- Merck and Co recently announced that the European Medicines Agency (EMA) Commission on Human Pharmaceutical Products (CHMP) has issued an active review recommending approval of the anti-PD-1 therapy Keytruda (Rhida, generic name: pembrolizumab, Pabliju monoanti), as a single-drug therapy, first-line treatment metastatic, microsatellite instability high (MSI-H) or mismatch repair defects (dMMR) colorectal cancer (mCRC) adult patients.
-
Nat Biomed Engin: Breakthrough! Chinese scientists have developed a new technology to detect SARS-CoV-2 infections without PCR amplification and can be detected in less than an hour!
Time of Update: 2020-12-27
Photo Source: SIBET's use of monoclonal antibody S9.6 is a prominent feature of the technology's development process, which helps identify the hybrid double strands of DNA-RNA and transforms nucleic acid detection into immunofluorescence on a simple lateral flow test strip (Lateral flow dipstick, LFD).
-
NEJM releases latest results from clinical trial of Pfizer's new crown vaccine BNT162b2, with 95% effective in preventing new coronavirus infections
Time of Update: 2020-12-27
13, 2020 /--- -- The full results of the Pfizer-BioNTech COVID-19 vaccine BNT162b2 clinical trial were published in the journal New England Journal of Medicine under the title "Safety and Efficacy of BNT162b2 mRNA Covid-19 Vaccine," according to a new report.
-
Inter Immunopharma: The new method predicts the effectiveness and risks of immunotherapy
Time of Update: 2020-12-27
12, 2020 /--- In a new study, researchers at Uppsala University demonstrated how the monoclonal antibody drug lysoxidant interacts with the blood of healthy people and patients with chronic lymphatic leukemia.
-
Nature: Heavy! Scientists have identified a new key gene that could help develop COVID-19 therapy!
Time of Update: 2020-12-27
in this study, researchers targeted two key genes involved in the molecular process, the antiviral immune response and the inflammatory response to the lungs, and the results are expected to help clinicians understand how COVID-19 impairs lung function at the molecular level.
-
Special dermatitis (AD) new drug! AbbVie oral JAK inhibitor Rinvoq Phase 3 clinical efficacy beat Sanofi/Regenerative Dupixent!
Time of Update: 2020-12-27
results showed that in all three clinical studies, Rinvoq treatment significantly improved dermatic removal rates and itching levels in adult and adolescent patients with moderate to severe idiopathic dermatitis compared to placebo.
-
Twice a year! FDA approves new plan for Roche multiple sclerosis drug Ocrevus: Intravenous infusion reduced from 3.5 hours to 2 hours!
Time of Update: 2020-12-27
December 15, 2020 // -- Roche recently announced that the U.S. Food and Drug Administration (FDA) has approved Ocrevus (ocrelizumab) 2-hour infusion program, a new, shorter-time infusion program that is given twice a year to treat patients with multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS).
-
Slow-blocking lung triple therapy! AstraZeneta Trixeo Aerosphere has been approved in the EU and China is listed!
Time of Update: 2020-12-27
December 15, 2020 // -- AstraZeneca recently announced that the European Commission (EC) has approved Trixeo Aerosphere (Chinese commodity names®: Peregrine® Fog agents) for maintenance therapy in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD), specifically in patients who receive a combination of an inhaled corticosteroid (ICS) and a long-acting beta-2-receiving atrial atrium (LABA), or a combination of LABA and a long-acting venom-alkali antagonist (LAMA) that does not adequately control the condition.
-
mBio: Targeting uplift cells helps treat COVID-19
Time of Update: 2020-12-26
Mackow stressed that studies to determine endosthal cells and ACE2 functional reduction after SARS-CoV-2 infection are necessary to identify targets that can reduce symptoms in patients with COVID-19.
Recombinant ACE2 Expression Is Required for SARS-CoV-2 To Infect Primary Human Endothelial Cells and Induce Inflammatory and Procoagulative Responses, mBio (2020).
-
Oncogenesis: Rae Gongto extract helps treat pancreatic cancer
Time of Update: 2020-12-26
December 18, 2020 /--- City of Hope affiliate Translational Genomics Research Institute (TGen) researchers conducted a preclinical study results show that Lei Gongto, a Chinese herbal medicine used in
-
ACS sub-journal: Histogenetic deacetylase inhibitors help treat new coronary infections
Time of Update: 2020-12-26
By combining computational screening with an effective cell prosthetic virus system, a team led by Professor Yuan Shuguang of the Shenzhen Institute of Advanced Technology (SIAT) of the Chinese Academy of Sciences has confirmed that clinical histone deacetylase (HDAC) inhibitors can be effective in preventing SARS-CoV-2 and may be used against COVID-19.
